Canada's Natural Health Products (NHP) sector is at a critical juncture, where the promise of red tape reduction meets the harsh reality of persistent administrative burdens. The federal government's commitment to streamlining regulations is laudable, but the devil is in the details, and the recent updates reveal a complex landscape where meaningful reform is still a distant prospect.
The Promise of Red Tape Reduction
The Health Canada's Red Tape Reduction Report, released in September 2025, signaled a positive step towards modernizing the NHP sector. The government's intention to address licensing, labeling, and system operations is a welcome development, especially for the long-suffering industry. However, the devil is in the details, and the proposed measures may not deliver the expected relief.
Licensing: Streamlining or Streamlined?
One of the key areas of focus is licensing, where the government proposes shifting towards streamlined or notification-based approaches for lower-risk products. This is a positive move, as it acknowledges the industry's concerns with delays, backlogs, and duplicative review processes. However, the proposed measures may not deliver the expected relief. Streamlined licensing pathways that reduce front-end review time while retaining the same underlying evidence, labeling, and post-market requirements will have limited impact on overall compliance costs.
Labeling: Flexibility or Red Tape?
Another critical area is labeling, where the government has signaled openness to revisiting current requirements. This is a positive development, as previous regulatory changes introduced significant redesign and compliance costs, particularly for small and medium-sized enterprises (SMEs). However, the proposed measures may not deliver the expected flexibility. Labeling updates that do not address formatting rigidity, update triggers, and alignment with international approaches risk being perceived as additional red tape.
Hidden Red Tape: The Unseen Burden
The NHP sector continues to experience what many describe as 'hidden red tape', a burden that is driven not by regulation itself, but by how it is implemented by Health Canada. Companies report inconsistent interpretation of requirements, evolving and sometimes expanding evidence expectations, and a lack of predictability in the review process. Even when guidance documents and monographs exist, submissions are frequently subject to additional information requests, creating delays and increasing costs.
Good Manufacturing Practices (GMP): A Double-Edged Sword
Recent updates to GMP, particularly through revised guidance, further illustrate this trend. While the regulatory framework has not fundamentally changed, expectations have shifted towards more formalized quality management systems, including enhanced requirements for risk management, corrective and preventive actions (CAPA), change control, and internal audits. These changes have increased documentation and compliance burden, disproportionately affecting SMEs due to significant increases in costs in a short time period.
Cross-Border Disparities: An Uneven Playing Field
The competitiveness pressures are intensifying, and a key concern is the uneven enforcement landscape, particularly in cross-border e-commerce. Canada's '90-day personal importation' provision is increasingly used at a commercial scale, allowing foreign products to enter the market without meeting the same regulatory requirements as domestic products. This creates an uneven playing field, undermines compliant Canadian businesses, and raises broader questions about regulatory sovereignty and consumer protection.
The Way Forward: A Targeted and Outcomes-Focused Approach
Canada has an opportunity to reestablish itself as a global leader in the NHP sector. However, this will require moving beyond high-level commitments and ensuring that current reform initiatives translate into measurable, on-the-ground reductions in industry's burden. The industry is calling for licensing reforms that deliver meaningful reductions in both time and cost, a true modernization of labeling that prioritizes flexibility, greater consistency and transparency in evidence requirements and regulatory decision-making, operational improvements within Health Canada, and modernized enforcement approaches that address cross-border disparities and restore competitive balance.
In my opinion, the NHP sector's journey towards red tape reduction is a complex and challenging one. The proposed measures may not deliver the expected relief, and the industry's concerns with hidden red tape and cross-border disparities are valid. However, there is an opportunity for Canada to reestablish itself as a global leader in the NHP sector, but this will require a targeted and outcomes-focused approach. The industry's call for meaningful reforms is a call for action, and the government must respond with concrete measures that deliver real flexibility and reduce the administrative burden on the sector.
